Discover whether it's possible to have mixed dementia, specifically a combination of Alzheimer's and Lewy body dementia. This ...

The researchers from the Rollins School of Public Health and Emery School of Medicine are partnering with the University of California, Davis, the University of British Columbia, and Georgia Tech to ...

A new study finds that brain shrinkage in Alzheimer’s disease varies greatly among individuals, with distinct patterns rather than a uniform progression. These findings may pave the way for ...

A quick finger prick and a few drops of blood on a card that can be sent in regular mail—This approach could soon make ...

That Thursday, for the first time, the European Medicines Agency (EMA) approved a drug that targets the cause — not just the ...

Researchers have created a highly detailed cellular map of Alzheimer’s disease progression, revealing new insights into the ...

A once-a-day pill that targets the production of the stress hormone cortisol in the brain has the potential to be the “holy ...

The first drug targeting the root cause of Alzheimer’s disease has been approved by the European Medicines Agency. Despite ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

In the rapidly evolving field of neuroimaging, the convergence of engineering advancements and medical expertise is reshaping our approach to understanding and treating neurological disorders. This ...